Navigation Links
Amicus Therapeutics Announces First Quarter 2008 Financial Results
Date:5/13/2008

the completion of the Phase 1 clinical trials for AT2220 for the treatment of Pompe disease, the start of Phase 2 studies for AT2220 and the possibility and timing of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with US and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and metabolic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward looking statements. Important factors that may cause actual results to differ materially from those indicated by forward looking statements include, among others, the potential that results of clinical or preclinical studies indicate that product candidates are unsafe or ineffective, our dependence on third parties in the conduct of our clinical studies, delays or failure to achieve regulatory approvals, risks of relying on third party manufacturers for the supply of our product candidates, we or our licensors may not be able to obtain, maintain and successfully enforce adequate patent and other intellectual property protection of our product candidates and risks of collaborating with third parties to develop and commercialize products. Th
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015 Working in collaboration with ... London , Richmond Pharmacology is the first ... 3 study for an investigational RNAi therapeutic being developed for ... the nerves and heart. Read press release ... Based at St Georges University of London ...
(Date:3/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ... providing advanced testing solutions for the detection of ... the three months and full year ended December ... Results:Revenue for the quarter ended December 31, 2014 ... fourth quarter of 2013 and $1.5 million for ...
(Date:3/26/2015)... 2015  BioNano Genomics, Inc., the leader in genome ... as chief commercial officer. Salyer has more than 20 ... in life sciences. At BioNano, Salyer will oversee the ... platform to assemble a comprehensive view of complex genomes ... 32 institutions located in the United States ...
(Date:3/26/2015)... 2015 ReliantHeart, Inc., an innovative supplier ... supplier of precision transit-time flow measurement solutions, are collaborating ... the efficiency of the HeartAssist5® Left Ventricular ... experience greater mobility and peace of mind. , ... board, will draw 1/6th of the power required by ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 2LVAD patients to have greater mobility and peace of mind through Transonic and ReliantHeart’s True Flow collaboration for the HeartAssist5® 3
... has purchased a LEAP 3000 metrology system made by ... Wis. The Tohoku University system is the third system Imago has ... system in conjunction with its representatives based in Japan, the Noah ... enabling metrology at the atomic scale. , , ...
... - In Victorian England, the game of croquet was ... matter, and people could share the latest news without inhibition. ... goal of a research team working from the University ... to capture that sense of interactivity and bring it to ...
... you noticed recently the earnest discussions about a seemingly inalienable ... maybe that overstates the argument a little bit, but the ... their blogging activities on what Apple considered competitive secrets is ... in various media. , ,Then in the not-quite-yet-news bin one ...
Cached Biology Technology:The Croquet Project: An open source solution to the OS monopoly 2The Croquet Project: An open source solution to the OS monopoly 3The Croquet Project: An open source solution to the OS monopoly 4The Croquet Project: An open source solution to the OS monopoly 5Social engineering - Coming to an IT ship near you? 2Social engineering - Coming to an IT ship near you? 3
(Date:3/10/2015)... -- Continuing its 167-year history of offering the Best, the ... Eye Scanning Password Authenticator , a device that confirms ... or sensitive data. Employing the same biometric ... device has a small camera that scans and saves ... them into an encrypted ID that cannot be forged ...
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of the "Global Biometrics ... their offering. The market for biometric ... CAGR of around 14% till 2020 ... will be increasing security needs, government projects and ...
(Date:2/25/2015)... 2015  ABC Financial Services (ABC), the leading ... and Fitness Industry, today announced enhancements to their ... latest upgrade includes advances to the agreement section ... via Identity One fingerprint biometrics. The features will ... displays at the International Health, Racquet & Sportsclub ...
Breaking Biology News(10 mins):Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... a component of salt, are elevated in many urban streams ... government study. Chloride levels above the recommended federal criteria ... 40 percent of urban streams tested. The study was ... chloride can inhibit plant growth, impair reproduction, and reduce the ...
... 16th 2009 / b3c newswire / - NiKem Research ... the Italian Ministry of Health, GLP certification of its bioanalysis ... NiKem Research has provided for many years high quality cost-effective ... ADME(T) and in vivo PK services associated to ...
... including the University of Colorado at Boulder have sequenced ... species, providing information that can be used to better ... Identifying such DNA barcodes can help wildlife officials ... species are in sharp decline from illegal trade estimated ...
Cached Biology News:Chloride found at levels that can harm aquatic life in urban streams of the Northern US 2NiKem Research receives certification for GLP Bioanalysis 2CU-Boulder team identifies DNA "barcodes to help track illegal trading of wildlife products 2CU-Boulder team identifies DNA "barcodes to help track illegal trading of wildlife products 3
... MBP Coated Microplate, 96 Well Anti-phospho-MBP, ... Magnesium/ATP Cocktail, #20-11 Blocking Buffer, 10X, ... LumiGLO™ Chemiluminescen Applications: ... Routinely evalauted by non-radioactive ...
... ActivePro In Vitro Translation ... E.coli lysate, synthesizes higher ... well as proteins with ... competing kits. This results ...
One-step, microplate or cuvet, colorimetric, detection range 0.3 g/dL to 5 g/dL. Procedure: 5 min....
The Varian 4000 GC/MS system offers three easily switchable ionization configurations: internal ionization (II), external ionization (EI) or hybrid chemical ionization (CI)...
Biology Products: